122 related articles for article (PubMed ID: 24614285)
21. P7170, a novel inhibitor of mTORC1/mTORC2 and Activin receptor-like Kinase 1 (ALK1) inhibits the growth of non small cell lung cancer.
Venkatesha VA; Joshi A; Venkataraman M; Sonawane V; Bhatia D; Tannu P; Bose J; Choudhari S; Srivastava A; Pandey PK; Lad VJ; Sangana R; Ahmed T; Damre A; Deore V; Sahu B; Kumar S; Sharma S; Agarwal VR
Mol Cancer; 2014 Dec; 13():259. PubMed ID: 25466244
[TBL] [Abstract][Full Text] [Related]
22. Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma.
Baumann P; Schneider L; Mandl-Weber S; Oduncu F; Schmidmaier R
Anticancer Drugs; 2012 Jan; 23(1):131-8. PubMed ID: 21959532
[TBL] [Abstract][Full Text] [Related]
23. The dual PI3K/mTOR inhibitor BEZ235 is effective in lung cancer cell lines.
Herrera VA; Zeindl-Eberhart E; Jung A; Huber RM; Bergner A
Anticancer Res; 2011 Mar; 31(3):849-54. PubMed ID: 21498705
[TBL] [Abstract][Full Text] [Related]
24. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
25. A novel imidazopyridine PI3K inhibitor with anticancer activity in non-small cell lung cancer cells.
Lee H; Kim SJ; Jung KH; Son MK; Yan HH; Hong S; Hong SS
Oncol Rep; 2013 Aug; 30(2):863-9. PubMed ID: 23708425
[TBL] [Abstract][Full Text] [Related]
26. Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells.
Chen X; Zhou JY; Zhao J; Chen JJ; Ma SN; Zhou JY
Anticancer Drugs; 2013 Nov; 24(10):1039-46. PubMed ID: 23962905
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.
Li H; Jin X; Zhang Z; Xing Y; Kong X
Cell Biochem Funct; 2013 Jul; 31(5):427-33. PubMed ID: 23086777
[TBL] [Abstract][Full Text] [Related]
28. Combined tamoxifen and gefitinib in non-small cell lung cancer shows antiproliferative effects.
Shen H; Yuan Y; Sun J; Gao W; Shu YQ
Biomed Pharmacother; 2010 Feb; 64(2):88-92. PubMed ID: 20005069
[TBL] [Abstract][Full Text] [Related]
29. Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor.
Mantha AJ; Hanson JE; Goss G; Lagarde AE; Lorimer IA; Dimitroulakos J
Clin Cancer Res; 2005 Mar; 11(6):2398-407. PubMed ID: 15788691
[TBL] [Abstract][Full Text] [Related]
30. Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines.
La Monica S; Galetti M; Alfieri RR; Cavazzoni A; Ardizzoni A; Tiseo M; Capelletti M; Goldoni M; Tagliaferri S; Mutti A; Fumarola C; Bonelli M; Generali D; Petronini PG
Biochem Pharmacol; 2009 Sep; 78(5):460-8. PubMed ID: 19427302
[TBL] [Abstract][Full Text] [Related]
31. Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells.
Janmaat ML; Rodriguez JA; Gallegos-Ruiz M; Kruyt FA; Giaccone G
Int J Cancer; 2006 Jan; 118(1):209-14. PubMed ID: 16003751
[TBL] [Abstract][Full Text] [Related]
32. Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations.
Konstantinidou G; Bey EA; Rabellino A; Schuster K; Maira MS; Gazdar AF; Amici A; Boothman DA; Scaglioni PP
Cancer Res; 2009 Oct; 69(19):7644-52. PubMed ID: 19789349
[TBL] [Abstract][Full Text] [Related]
33. PI3K/mTOR dual inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A synergistically exert anti-tumor activity in breast cancer.
Chen L; Jin T; Zhu K; Piao Y; Quan T; Quan C; Lin Z
Oncotarget; 2017 Feb; 8(7):11937-11949. PubMed ID: 28060760
[TBL] [Abstract][Full Text] [Related]
34. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib.
Morgillo F; Woo JK; Kim ES; Hong WK; Lee HY
Cancer Res; 2006 Oct; 66(20):10100-11. PubMed ID: 17047074
[TBL] [Abstract][Full Text] [Related]
35. Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake.
Fuereder T; Wanek T; Pflegerl P; Jaeger-Lansky A; Hoeflmayer D; Strommer S; Kuntner C; Wrba F; Werzowa J; Hejna M; Müller M; Langer O; Wacheck V
Clin Cancer Res; 2011 Aug; 17(16):5322-32. PubMed ID: 21712451
[TBL] [Abstract][Full Text] [Related]
36. The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells.
Simioni C; Cani A; Martelli AM; Zauli G; Alameen AA; Ultimo S; Tabellini G; McCubrey JA; Capitani S; Neri LM
Oncotarget; 2015 Jul; 6(19):17147-60. PubMed ID: 26003166
[TBL] [Abstract][Full Text] [Related]
37. Enediyne lidamycin enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib, in epidermoid carcinoma A431 cells and lung carcinoma H460 cells.
Liu H; Li L; Li XQ; Liu XJ; Zhen YS
Anticancer Drugs; 2009 Jan; 20(1):41-9. PubMed ID: 19342999
[TBL] [Abstract][Full Text] [Related]
38. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
[TBL] [Abstract][Full Text] [Related]
39. In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines.
Cheng H; An SJ; Zhang XC; Dong S; Zhang YF; Chen ZH; Chen HJ; Guo AL; Lin QX; Wu YL
Cancer Chemother Pharmacol; 2011 Mar; 67(3):637-46. PubMed ID: 20495920
[TBL] [Abstract][Full Text] [Related]
40. The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer.
Shukuya T; Yamada T; Koenig MJ; Xu J; Okimoto T; Li F; Amann JM; Carbone DP
J Thorac Oncol; 2019 Jun; 14(6):1061-1076. PubMed ID: 30825612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]